Economic evaluation of denosumab compared with zoledronic acid in hormone-refractory prostate cancer patients with bone metastases

Journal of Managed Care Pharmacy

Volumn 17, Issue 8, 2011, Pages 621-634

  Xie, Jipan ^a   Namjoshi, Madhav ^a   Wu, Eric Q ^a   Parikh, Kejal ^a   Diener, Melissa ^a   Yu, Andrew P ^a   Guo, A ^b   Culver, Kenneth W ^b  

^a ANALYSIS GROUP   (United States)

^b NOVARTIS PHARMA AG   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN; ANTIHISTAMINIC AGENT; ANTIPERSPIRANT AGENT; CHENODEOXYCHOLIC ACID; CHLORHEXIDINE; DENOSUMAB; DIPHENHYDRAMINE; GLUCONATE CALCIUM; IBUPROFEN; INSULIN; PARACETAMOL; POTASSIUM DIHYDROGEN PHOSPHATE; URSODEOXYCHOLIC ACID; ZANAMIVIR; ZOLEDRONIC ACID;

ALKALINE PHOSPHATASE BLOOD LEVEL; ARTICLE; BONE METASTASIS; BONE NECROSIS; CANCER GROWTH; CANCER MORTALITY; CEREBROVASCULAR ACCIDENT; CHILL; CHOLELITHIASIS; COGNITIVE DEFECT; CONSULTATION; COST EFFECTIVENESS ANALYSIS; COST OF ILLNESS; DRUG COST; DRUG HYPERSENSITIVITY; ECONOMIC EVALUATION; FEVER; FLU LIKE SYNDROME; FRACTURE; GLUCOSE BLOOD LEVEL; HEALTH CARE COST; HEALTH CARE PERSONNEL; HEALTH CARE UTILIZATION; HERPETIC STOMATITIS; HUMAN; HYPERCALCEMIA; HYPERHIDROSIS; HYPOCALCEMIA; HYPOPHOSPHATEMIA; INFLUENZA; LITHOTRIPSY; MALE; MUSCLE SPASM; MYALGIA; PROSTATE CANCER; SENSITIVITY ANALYSIS; SIDE EFFECT; SINUSITIS; TOOTH ABSCESS; TOOTH PAIN; VERTEBRA FRACTURE;

EID: 83255193295     PISSN: 10834087     EISSN: None     Source Type: Journal    
DOI: 10.18553/jmcp.2011.17.8.621     Document Type: Article

References (33)

1. American Cancer Society. Cancer facts and figures 2010. Atlanta, GA: American Cancer Society; 2010. Available at: http://www.cancer.org/acs/groups/content/@nho/documents/document/acspc-024113.pdf. Accessed September 13, 2011.
2. Mariotto AB, Yabroff KR, Shao Y, Feuer EJ, Brown ML. Projections of the cost of cancer care in the United States: 2010-2020. J Natl Cancer Inst. 2011;103(2):117-28.
3. Schulman KL, Kohles J. Economic burden of metastatic bone disease in the U.S. Cancer. 2007;109(11):2334-42. Available at: http://onlinelibrary.wiley.com/doi/10.1002/cncr.22678/pdf. Accessed September 13, 2011.
4. Coleman RE. Metastatic bone disease: clinical features, pathophysiology and treatment strategies. Cancer Treat Rev. 2001;27(3):165-76.
5. Lage MJ, Barber BL, Harrison DJ, Jun S. The cost of treating skeletal-related events in patients with prostate cancer. Am J Manag Care. 2008;14(5):317-22.
6. Reed SD, Radeva JI, Glendenning GA, Saad F, Schulman KA. Costeffectiveness of zoledronic acid for the prevention of skeletal complications in patients with prostate cancer. J Urol. 2004;171(4):1537-42.
7. U.S. Food and Drug Administration. Zoledronic acid (Zometa, Novartis) approval for the treatment of patients with documented bone metastases from solid tumors. February 22, 2002. Available at: http://www.accessdata.fda.gov/drugsatfda_docs/appletter/2002/21223s3ltr.pdf. Accessed September 13, 2011.
8. Zometa. (zoledronic acid) for intravenous infusion. Novartis. Revised June 2011. Available at: www.pharma.us.novartis.com/product/pi/pdf/Zometa.pdf. Accessed September 13, 2011.
9. Saad F, Gleason DM, Murray R, et al. A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J Natl Cancer Inst. 2002;94(19):1458-68. Available at: http://jnci.oxfordjournals.org/content/94/19/1458.full.pdf+html. Accessed September 13, 2011.
10. Saad F, Chen YM, Gleason DM, Chin J. Continuing benefit of zoledronic acid in preventing skeletal complications in patients with bone metastases. Clin Genitourin Cancer. 2007;5(6):390-96. Available at: http://cigjournals.metapress.com/content/v855363j6u821k66/fulltext.pdf. Accessed September 13, 2011.
11. U.S. Food and Drug Administration. Denosumab (Xgeva, Amgen) approval for the prevention of skeletal-related events in patients with bone metastases from solid tumors. November 18, 2010. Available at: http://www.accessdata.fda.gov/drugsatfda_docs/appletter/2010/125320s007ltr.pdf. Accessed September 13, 2011.
12. Xgeva. (denosumab) for subcutaneous injection. Amgen. Revised November 2010. Available at: http://pi.amgen.com/united_states/xgeva/xgeva_pi.pdf. Accessed September 13, 2011.
13. Miller PD. Denosumab: anti-RANKL antibody. Curr Osteoporos Rep. 2009;7(1):18-22.
14. Fizazi K, Carducci M, Smith M, et al. Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study. Lancet. 2011;377(9768):813-22.
15. ReadyPrice software. Red Book 2010: Pharmacy's Fundamental Reference (Red Book Drug Topics). Montvale, NJ: Thomson Healthcare; November 2010.
16. West H. Denosumab. for prevention of skeletal-related events in patients with bone metastases from solid tumors: incremental benefit, debatable value. J Clin Oncol. 2011;29(9):1095-98. Available at: http://jco.ascopubs.org/content/early/2011/02/16/JCO.2010.33.5596.full.pdf. Accessed September 13, 2011.
17. Hillner BE, Weeks JC, Desch CE, Smith TJ. Pamidronate in prevention of bone complications in metastatic breast cancer: a cost-effectiveness analysis. J Clin Oncol. 2000;18(1):72-79. Available at: http://171.66.121.246/content/18/1/72.full.pdf+html. Accessed September 13, 2011.
18. Goldberg LD, Edwards NC, Fincher C, Doan QV, Al-Sabbagh A, Meletiche DM. Comparing the cost-effectiveness of disease-modifying drugs for the first-line treatment of relapsing-remitting multiple sclerosis. J Manag Care Pharm. 2009;15(7):543-55. Available at: http://www.amcp.org/data/jmcp/543-555.pdf.
19. Tchekmedyian NS, Chen YM, Saad F. Disease progression increases the risk of skeletal-related events in patients with bone metastases from castration-resistant prostate cancer, lung cancer, or other solid tumors. Cancer Invest. 2010;28(8):849-55.
20. U.S. Bureau of Labor Statistics. Consumer Price Index: CPI tables. Available at: http://www.bls.gov/cpi/tables.htm. Accessed September 13, 2011.
21. Centers for Medicare & Medicaid Services. Physician fee schedule database. Updated June 7, 2011. Available at: http://www.cms.hhs.gov/Pfslookup/(Physicianfees) and http://www.cms.hhs.gov/ClinicalLabFeeSched/02_clinlab.asp(Clinicallaboratoryfees). Accessed September 13, 2011.
22. Federal Register.gov. Statewide average operating cost-to-charge ratios for urban and rural hospitals (case weighted) March 2000. Medicare program: changes to the hospital inpatient prospective payment systems and fiscal year 2001 rates. Available at: http://www.federalregister.gov/articles/2000/08/01/00-19108/medicare-program-changes-to-the-hospitalinpatient-prospective-payment-systems-and-fiscal-year-2001#t-37. Accessed September 13, 2011.
23. U.S. Census Bureau. United States-states. GCT-T1. Population estimates. Available at: http://factfinder.census.gov/servlet/GCTTable?_bm=y&-geo_id=01000US&-_box_head_nbr=GCT-T1&-ds_name=PEP_2009_EST&-_lang=en&-format=US-40&-_sse=on. Accessed September 13, 2011.
24. Penson DF, Moul JW, Evans CP, Doyle JJ, Gandhi S, Lamerato L. The economic burden of metastatic and prostate specific antigen progression in patients with prostate cancer: findings from a retrospective analysis of health plan data. J Urol. 2004;171(6 Pt 1):2250-54.
25. Yabroff KR, Lamont EB, Mariotto A, et al. Cost of care for elderly cancer patients in the United States. J Natl Cancer Inst. 2008;100(9):630-41. Available at: http://jnci.oxfordjournals.org/content/100/9/630.full.pdf+html. Accessed September 13, 2011.
26. Fizazi K. Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with castration-resistant prostate cancer. Presented at: 2010 ASCO Annual Meeting; June 4-8, 2010; Chicago, IL. Slide available upon request. Available at: http://www.asco.org/ascov2/Meetings/Abstracts?&vmview=abst_detail_view&confID=74&abstractID=51444. Accessed September 13, 2011.
27. Applegate SE, Lim DS. Incidence of stroke in patients with d-transposition of the great arteries that undergo balloon atrial septostomy in the University Healthsystem Consortium Clinical Data Base/Resource Manager. Catheter Cardiovasc Interv. 2010;76(1):129-31.
28. Agency for Healthcare Research and Quality. Healthcare Cost and Utilization Project: welcome to HCUPnet. Available at: http://hcupnet.ahrq.gov/HCUPnet.jsp. Accessed September 13, 2011.
29. New Choice Health. Lithotripsy (kidney stone removal surgery) procedure & cost information. Available at: http://www.newchoicehealth.com/Directory/Procedure/136/Lithotripsy%20%28Kidney%20Stone%20Removal%20Surgery%29. Accessed September 13, 2011.
30. Drugstore.com. Drugstore prices. Available at: www.drugstore.com. Accessed September 13, 2011.
31. Manski RJ, Brown E. Dental use, expenses, private dental coverage, and changes, 1996 and 2004. Rockville, MD: Agency for Healthcare Research and Quality; 2007. MEPS Chartbook No. 17. Available at: www.meps.ahrq.gov/mepsweb/data_files/publications/cb17/cb17.pdf. Accessed September 13, 2011.
32. Snedecor SJ, Carter JA, Kaura S, Botteman M. Cost-effectiveness of zoledronic acid (ZOL) versus denosumab (Dmab) in prevention of skeletalrelated events (SREs) in castration-resistant prostate cancer metastatic to the bone (mCRPC). Poster presented at: 2011 ASCO Annual Meeting; June 3-7, 2011; Chicago IL. J Clin Oncol. 29: 2011 (suppl; abstr 4581). Available at: http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=102&abstractID=76726. Accessed September 13, 2011.
33. Hatoum HT, Lin SJ, Smith MR, Barghout V, Lipton A. Zoledronic acid and skeletal complications in patients with solid tumors and bone metastases: analysis of a national medical claims database. Cancer. 2008;113(6):1438-45. Available at: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2900766/pdf/nihms204595.pdf. Accessed September 13, 2011.